Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Tonya Fraser

Physician Assistant, Medical Charlotte, NC Physician Assistant

NPI 1508839226 CMS profile 10918900

11304 Hawthorne Drive, Suite 100, Charlotte, NC 28227

Open in the dashboard

General payments

$15,541

823 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Tonya Fraser of Charlotte, NC is reported in the CMS Open Payments database as having received $15,541 across 823 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,196 152
2024 General $3,286 165
2023 General $3,518 173
2022 General $2,900 174
2021 General $2,641 159

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Tonya Fraser
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Tonya Fraser were reported at $3,196. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Tonya Fraser Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $2,641 $156 $41–$563 $132
2022 $2,900 $185 $55–$649 $149
2023 $3,518 $199 $58–$717 $160
2024 $3,286 $206 $62–$740 $164
2025 $3,196 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $2,352 129 payments
  2. Novo Nordisk Inc $1,859 106 payments
  3. Pfizer Inc. $1,636 84 payments
  4. Bayer HealthCare Pharmaceuticals Inc. $922 57 payments
  5. AstraZeneca Pharmaceuticals LP $908 40 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $734 35 payments
  7. Exact Sciences Corporation $630 14 payments
  8. Lilly USA, LLC $578 30 payments
  9. Astellas Pharma US Inc $540 25 payments
  10. Amgen Inc. $389 27 payments
  11. Other $4,992 276 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $15,441 822 payments
  2. Education $100 1 payment
Products named General payments · program years 2021–2025
  1. UBRELVY $1,185 65 payments
  2. Kerendia $922 57 payments
  3. RYBELSUS $917 60 payments
  4. Ozempic $852 57 payments
  5. NURTEC ODT $652 41 payments
  6. Cologuard Collection Kit $630 14 payments
  7. ZAVZPRET $623 35 payments
  8. PREVNAR 20 $588 25 payments
  9. QULIPTA $569 18 payments
  10. Wegovy $559 29 payments
  11. Other $12,600 678 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 65 drugs

Part D claims

1,997

Median for Physician Assistant: 241

Drug cost

$179,461

Median for Physician Assistant: $4,110

Branded share of claims

20.8%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Rybelsus Semaglutide Brand 33 $38,558
Ozempic Semaglutide Brand 18 $29,184
Mounjaro Tirzepatide Brand 21 $23,981
Farxiga Dapagliflozin Propanediol Brand 22 $20,509
Jardiance Empagliflozin Brand 14 $14,744
Repatha Sureclick Evolocumab Brand 13 $14,356
Trulicity Dulaglutide Brand 12 $12,715
Synthroid Levothyroxine Sodium Brand 39 $4,112
Nebivolol Hcl Generic 14 $1,628
Olmesartan Medoxomil Generic 101 $1,514

The 10 drugs with the highest cost, of 65 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 21 billing codes

Paid by Medicare

$32,644

Medicare's payments for the services billed

Medicare patients

194

Average age 74

Services billed

706

139 women, 55 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Arthritis 37%
Depression 23%
Chronic kidney disease 22%
Diabetes 19%
Ischemic heart disease 18%
Osteoporosis 16%
Cancer 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 42 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Kerendia
$237 — —
JARDIANCE
$168 14 —
Veozah
$145 — —
QULIPTA
$140 — —
Wegovy
$139 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 42 with Patron

Records

823 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record